Clinical trials: HCM - Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy
HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is the most common monogenic heart disease and the most frequent cause of sudden cardiac death (SCD) in the young.
- Trial name
- HCMR (NCT01915615)
- Testing
- None - this is an observational study
- Where
- 44 sites in United States, Canada and 4 more
- Volunteers
- 2,750 people
- Sponsor
- University of Virginia
Hypertrophic Cardiomyopathy
Biventricular Pacing in Hypertrophic Cardiomyopathy After Aortic Valve Replacement
Biventricular Pacing has been shown an improvement of symptoms in patients with heart failure. A temporary pacing is necessary in patients after cardiac procedures.
- Trial name
- BIVENT (NCT01081093)
- Testing
- additional temporary pacewire
- Where
- Germany
- Volunteers
- 72 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Hypertrophic Cardiomyopathy (HCM)
Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy
This study is being performed to understand the effect of different doses of CK-3773274 on patients with hypertrophic cardiomyopathy (HCM).
- Trial name
- REDWOOD-HCM (NCT04219826)
- Testing
- CK-3773274 (5 - 15 mg), CK-3773274 (10 - 30 mg)
- Where
- 22 sites in United States, Italy and 2 more
- Volunteers
- 96 people
- Sponsor
- Cytokinetics
Friedreich Ataxia, Cardiomyopathy, Secondary
Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
The purpose of Study LX2006-03, a multicenter, Phase 2, open-label, randomized, controlled study, is to evaluate the efficacy and safety of LX2006 gene therapy in participants with Friedreich ataxia (FA) cardiomyopathy (CM).
- Trial name
- SUNRISE-FA 2 (NCT07721025)
- Testing
- LX2006, Usual Care
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Lexeo Therapeutics
Fabry Disease, Fabry Disease, Cardiac Variant
Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalence and Implementation of a Clinical Score
This study aims to evaluate the prevalence of Fabry Disease (FD) among a cohort of high risk patients with left ventricular hypertrophy (LVH) presenting at the University Hospital Würzburg over the last 20 years.
- Conditions
- Fabry Disease, Fabry Disease, Cardiac Variant, Lysosomal Storage Diseases, HCM - Hypertrophic Cardiomyopathy
- Trial name
- FAPREV-HCM (NCT04943991)
- Testing
- blood sampling (alpha-Galactosidase & LysoGb3)
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Wuerzburg University Hospital
Hypertrophic Cardiomyopathy (HCM)
Multicentre Hypertrophic Cardiomyopathy Registry
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart condition, affecting approximately 1 in 500 people. It causes the heart muscle to thicken, which can lead to blockages in blood flow (left ventricular outflow…
- Trial name
- NCT07381894
- Where
- United Kingdom
- Volunteers
- 2,500 people
- Sponsor
- University of Manchester
Implantable Defibrillator User, Hypertrophic Cardiomyopathy
Pilot Study of Hypertrophic Cardiomyopathy & Implantable Cardioverter Defibrillator Assessment: (Subcutaneous vs Transvenous)
Pilot randomised trial to assess recruitment for a larger trial to compare the efficacy and adverse effects of the subcutaneous and transvenous ICD in patients with hypertrophic cardiomyopathy (HCM) and indication for ICD…
- Conditions
- Implantable Defibrillator User, Hypertrophic Cardiomyopathy, Implantable Cardioverter Ventricular Lead Dysfunction or Complication, Ventricular Arrythmia
- Trial name
- HICD (NCT05938283)
- Testing
- Implantable Cardioverter Defibrillator implant
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Barts & The London NHS Trust
Hypertrophic Cardiomyopathy
Egyptian Hypertrophic Cardiomyopathy Program
Egyptian HCM program aims at defining incidence, severity, phenotype, genotype and determinants of the disease in Egypt, and providing state-of-the-art treatment strategies including medical, surgical and interventional…
- Trial name
- NCT05884892
- Where
- Egypt
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Magdi Yacoub Heart Foundation
Obstructive Hypertrophic Cardiomyopathy
Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM
The goal of this observational study is to measure the effect of mavacamten treatment on blood flow in the heart muscle (myocardium) in patients with obstructive hypertrophic cardiomyopathy.
- Trial name
- MavaPET (NCT06023186)
- Testing
- mavacamten
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Michael Ayers
Non-ischemic Cardiomyopathy, DCM - Dilated Cardiomyopathy
DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies
The DZHK TranslatiOnal Registry for CardiomyopatHies (DZHK TORCH) represents a unique resource of clinical data and high quality biological samples to enable innovative clinical and molecular studies on cardiomyopathies (CMP).
- Conditions
- Non-ischemic Cardiomyopathy, DCM - Dilated Cardiomyopathy, HCM - Hypertrophic Cardiomyopathy, HOCM - Hypertrophic Obstructive Cardiomyopathy
- Trial name
- TORCH-Plus (NCT04265040)
- Where
- Germany
- Volunteers
- 2,040 people
- Sponsor
- University Hospital Heidelberg
Hypertrophic Cardiomyopathy, Hypertrophic Cardiomyopathy, Obstructive
Assessment of Cardiac Function, Microvascular Function and Cardiac Perfusion in Different Disease Stages of Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by asymmetric hypertrophy of the heart in absence of loading conditions like hypertension.
- Trial name
- FUSION-HCM (NCT06400524)
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Amsterdam UMC, location VUmc
Primary Cardiomyopathy, Dilated Cardiomyopathy
Risk Stratification in Children and Adolescents With Primary Cardiomyopathy
RIKADA is a prospective study performing systematic family screening including clinical and genetic testing in pediatric patients with primary cardiomyopathy and their first-degree relatives with the aim to facilitate risk…
- Conditions
- Primary Cardiomyopathy, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Left Ventricular Noncompaction
- Trial name
- RIKADA (NCT03572569)
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- German Heart Institute
Obstructive Hypertrophic Cardiomyopathy
Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.
- Trial name
- COMPASS-HCM (NCT06551129)
- Testing
- Mavacamten
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Bristol-Myers Squibb
Sudden Cardiac Arrest, Sudden Arrhythmic Death Syndrome
Hearts in Rhythm Organization (HiRO)National Registry and Bio Bank
The Hearts in Rhythm Organization (HiRO) is a national network of Canadian researchers/clinicians, working towards a better understanding of the rare genetic causes of sudden cardiac death (SCD).
- Conditions
- Sudden Cardiac Arrest, Sudden Arrhythmic Death Syndrome, Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), Long QT Syndrome (LQTS)
- Trial name
- HiRO (NCT04189822)
- Where
- Canada
- Volunteers
- 10,000 people
- Sponsor
- University of British Columbia
Hypertrophic Obstructive Cardiomyopathy \(HOCM\)
Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy
Background: Microvascular dysfunction is a hallmark of hypertrophic obstructive cardiomyopathy (HOCM) and can be visualized non-invasively using cardiac magnetic resonance (CMR) perfusion imaging.
- Trial name
- oHCM (NCT07150299)
- Testing
- Mavacamten in clinical routine use
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Medical University of Vienna
Hypertrophic Cardiomyopathy, Depression
Efficacy of Psychotherapy for Improving Quality of Life in Patients With Hypertrophic Cardiomyopathy and Depression
A Study to evaluate the efficacy of psychotherapy for easing the cardiac symptoms and improving and quality of life in patients with hypertrophic cardiomyopathy accompanied with depression
- Conditions
- Hypertrophic Cardiomyopathy, Depression, Anxiety, Psychotherapy
- Trial name
- NCT03706001
- Testing
- Psychotherapy
- Volunteers
- 100 people
- Sponsor
- Xijing Hospital
HCM - Hypertrophic Cardiomyopathy, Sudden Cardiac Death
Left Bundle Branch Pacing in Patients With Hypertrophic Cardiomyopathy After Myectomy
Pilot interventional randomized clinical trial to study the efficacy of left bundle branch pacing in patients with hypertrophic cardiomyopathy after myectomy for the prevention of progression of heart failure, prevent the…
- Conditions
- HCM - Hypertrophic Cardiomyopathy, Sudden Cardiac Death, Left Bundle Branch Pacing, ICD
- Trial name
- LEFTpaceHCM (NCT07372196)
- Testing
- ICD with left bundle branch area pacing (LBBAP), dual-chamber ICD
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Obstructive Hypertrophic Cardiomyopathy (oHCM)
A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US
The purpose of this study is to evaluate the real-world safety and effectiveness of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) initiated on mavacamten at certain high volume HCM centers in the US
- Trial name
- NCT07107373
- Testing
- Mavacamten
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Bristol-Myers Squibb
Cardiomyopathy
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
The objective of this study is to collect information on patients with cardiomyopathy (CM) due to mutations in the MYBPC3 gene, to evaluate their disease course, burden of illness, risk factors for this disease, and the quality…
- Trial name
- MyCLIMB (NCT05112237)
- Where
- 29 sites in United States, Canada and 2 more
- Volunteers
- 200 people
- Sponsor
- Tenaya Therapeutics
Long QT Syndrome, Brugada Syndrome
Physical Activity in Children With Inherited Cardiac Diseases
Use lay language. Current guidelines regarding physical activity in patients with inherited arrhythmia and cardiomyopathy are mostly dedicated to adult patients, with a special focus on sports competition.
- Conditions
- Long QT Syndrome, Brugada Syndrome, Catecholaminergic Polymorphic Ventricular Tachycardia, Hypertrophic Cardiomyopathy
- Trial name
- NCT04650009
- Where
- France
- Volunteers
- 28 people
- Sponsor
- University Hospital, Montpellier